NTRK2 and neuroblastoma: Specifically, overexpression of TrkA and TrkC is a favourable prognostic biomarker in neuroblastoma, while TrkB is often expressed in neuroblastomas with MYCN amplification, which per se is an unfavourable biological factor in these patients [9].